These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 22458576)

  • 21. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
    Kastrati A; Mehilli J; Pache J; Kaiser C; Valgimigli M; Kelbaek H; Menichelli M; Sabaté M; Suttorp MJ; Baumgart D; Seyfarth M; Pfisterer ME; Schömig A
    N Engl J Med; 2007 Mar; 356(10):1030-9. PubMed ID: 17296823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency, etiology, treatment, and outcomes of drug-eluting stent thrombosis during one year of follow-up.
    Sandhu G; Doyle B; Singh R; Bell M; Bresnahan J; Mathew V; Holmes D; Lerman A; Rihal C
    Am J Cardiol; 2007 Feb; 99(4):465-9. PubMed ID: 17293185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
    Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
    J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET.
    Pfisterer M; Brunner-La Rocca HP; Rickenbacher P; Hunziker P; Mueller C; Nietlispach F; Leibundgut G; Bader F; Kaiser C;
    Eur Heart J; 2009 Jan; 30(1):16-24. PubMed ID: 19033260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents.
    Wang TY; Hasselblad V; Peterson JL; Wijns W; Parhizgar A; Kereiakes DJ; Krucoff MW
    Am Heart J; 2007 May; 153(5):743-8. PubMed ID: 17452147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study).
    Patel MR; Pfisterer ME; Betriu A; Widmisky P; Holmes DR; O'Neill WW; Stebbins A; Van de Werf F; Armstrong PW; Granger CB;
    Am J Cardiol; 2009 Jan; 103(2):181-6. PubMed ID: 19121433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New generation coronary stent technology--is the future biodegradable?
    Sammel AM; Chen D; Jepson N
    Heart Lung Circ; 2013 Jul; 22(7):495-506. PubMed ID: 23548335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodegradable drug eluting stents: invasive and non-invasive imaging.
    Kukreja N; Otsuka M; van Mieghem C; Ligthart J; Sianos G; Serruys PW
    EuroIntervention; 2006 Nov; 2(3):403. PubMed ID: 19755321
    [No Abstract]   [Full Text] [Related]  

  • 37. Overview of biodegradable urethral stents.
    Azuma H; Chancellor MB
    Rev Urol; 2004; 6(2):98-9. PubMed ID: 16985588
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of biodegradable stents in octogenarians with achalasia.
    El Abiad R; Khashab MA
    Endosc Int Open; 2021 Jun; 9(6):E767-E769. PubMed ID: 34080587
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting.
    Tsai ML; Hsieh MJ; Chen CC; Chang SH; Wang CY; Chen DY; Yang CH; Yeh JK; Ho MY; Hsieh IC
    Acta Cardiol Sin; 2020 Mar; 36(2):97-104. PubMed ID: 32201459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodegradable polymer-coated versus durable polymer-coated sirolimus-eluting stents: the final 5-year outcomes of the I-LOVE-IT 2 trial.
    Xu K; Xu B; Guan C; Jing Q; Zheng Q; Li X; Zhao X; Wang H; Zhao X; Li Y; Li J; Yang Y; Han Y
    EuroIntervention; 2021 Apr; 16(18):e1518-e1526. PubMed ID: 32038026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.